Vaccinex to Chair Panel Q&A Session and Present Poster at the XV European Meeting on Glial Cells in Health and Disease
June 30, 2021 08:00 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., June 30, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology Company pioneering a differentiated approach to treating neurodegenerative disease...
Vaccinex Announces Activation of Clinical Sites to Enroll Patients in Studies of Pepinemab as Single Agent in Alzheimer’s Disease and in Combination with KEYTRUDA® in Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
June 08, 2021 07:00 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., June 08, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology Company pioneering a differentiated approach to treating neurodegenerative disease...
Vaccinex to Present at the Jefferies 2021 Virtual Healthcare Conference
May 19, 2021 08:00 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., May 19, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
Vaccinex Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 17, 2021 08:15 ET
|
Vaccinex, Inc.
Initiated Phase 2 study of pepinemab in combination with KEYTRUDA® in advanced, recurrent or metastatic head and neck cancer Announced publication of results from CLASSICAL-Lung phase 1b/2 clinical...
Vaccinex Announces Publication of Results from CLASSICAL-Lung Phase 1b/2 Clinical Trial in Non-Small Cell Lung Cancer in the Peer-Reviewed Journal Clinical Cancer Research
April 21, 2021 08:00 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., April 21, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and...
Vaccinex Reports Fourth Quarter 2020 Financial Results and Provides Corporate Update
March 16, 2021 08:05 ET
|
Vaccinex, Inc.
Reported top-line results from Phase 2 SIGNAL study that indicates potential cognitive benefit of pepinemab in neurodegenerative disease. New Alzheimer’s study expected to begin enrollment in Q2 ...
Vaccinex to Present at the Oppenheimer 31st Annual Healthcare Conference
March 11, 2021 08:00 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., March 11, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and...
Vaccinex Announces Licensing of Anti-CCR8 Antibody to Surface Oncology
February 22, 2021 08:30 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
Vaccinex Announces Signing of Two Multi-Project Deals with Leading Pharmaceutical Companies Focused on Leveraging Its ActivMAb® Platform
February 19, 2021 08:00 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
Vaccinex to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event
January 05, 2021 08:00 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...